BridgeBio Pharma (BBIO) Equity Average (2018 - 2026)

BridgeBio Pharma's Equity Average history runs 9 years deep, the most recent figure standing at -$2.2 billion for Q1 2026.

• In Q1 2026, Equity Average fell 40.64% year-over-year to -$2.2 billion; the TTM figure through Mar 2026 stood at -$2.2 billion (down 40.64% YoY), while the FY2025 annual figure was -$1.8 billion, down 26.55% from the prior year.
• Equity Average came in at -$2.2 billion for Q1 2026 at BridgeBio Pharma, down from -$2.0 billion in the prior quarter.
• In the past five years, Equity Average ranged from a high of -$954.0 million in Q1 2022 to a low of -$2.2 billion in Q1 2026.
• A 5-year average of -$1.4 billion and a median of -$1.3 billion in 2023 frame the typical range for Equity Average.
• Across the five-year window, Equity Average slumped 573.95% in 2022 and grew 17.33% in 2024, its largest moves.
• BridgeBio Pharma's Equity Average stood at -$1.2 billion in 2022, then retreated by 7.04% to -$1.3 billion in 2023, then slipped by 5.46% to -$1.3 billion in 2024, then sank by 50.17% to -$2.0 billion in 2025, then dropped by 8.33% to -$2.2 billion in 2026.
• According to Business Quant data, Equity Average over the past three periods registered -$2.2 billion, -$2.0 billion, and -$1.9 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison